PriceTargets.com logo

Zymeworks - ZYME Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 65.15%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$12.72 As of 04/30/2025 11:24 AM ET
▲ +0.026 (0.20%)

This chart shows the closing price for ZYME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zymeworks Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYME

Analyst Price Target is $21.00
▲ +65.15% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $21.00, with a high forecast of $30.00 and a low forecast of $13.00. The average price target represents a 65.15% upside from the last price of $12.72.

This chart shows the closing price for ZYME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in Zymeworks. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/6/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2025

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/11/2025Lifesci CapitalInitiated CoverageOutperform$30.00
3/10/2025HC WainwrightBoost TargetNeutral ➝ Neutral$12.00 ➝ $13.00
3/7/2025CitigroupBoost TargetBuy ➝ Buy$18.00 ➝ $19.00
12/19/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$12.00 ➝ $14.00
12/16/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$18.00
11/22/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
11/7/2024Leerink PartnrsUpgradeHold ➝ Strong-Buy
11/7/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$10.00 ➝ $25.00
11/4/2024CitigroupBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
11/1/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
11/1/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$12.00 ➝ $12.00
10/28/2024Stifel NicolausBoost TargetBuy ➝ Buy$21.00 ➝ $28.00
10/22/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$12.00 ➝ $12.00
9/25/2024HC WainwrightBoost TargetNeutral ➝ Neutral$10.00 ➝ $12.00
9/18/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
8/2/2024Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $21.00
6/6/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/7/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$10.00
5/3/2024CitigroupLower TargetBuy ➝ Buy$17.00 ➝ $16.00
5/3/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$14.00 ➝ $12.00
8/15/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$8.00
5/18/2023CitigroupBoost Target$17.00 ➝ $18.00
5/9/2023Stifel NicolausBoost Target$18.00 ➝ $19.00
3/31/2023JPMorgan Chase & Co.Boost TargetNeutral$8.00 ➝ $9.00
3/21/2023Wells Fargo & CompanyReiterated RatingOverweight$12.00
3/21/2023HC WainwrightReiterated RatingNeutral$8.00
3/10/2023CitigroupLower Target$21.00 ➝ $17.00
3/8/2023GuggenheimReiterated RatingBuy$16.00
1/24/2023HC WainwrightReiterated RatingNeutral$8.00
1/20/2023Leerink PartnersBoost TargetMarket Perform$8.00 ➝ $10.00
1/19/2023GuggenheimBoost Target$15.00 ➝ $16.00
1/4/2023HC WainwrightLower TargetNeutral$10.00 ➝ $8.00
12/22/2022BarclaysBoost TargetEqual Weight$7.00 ➝ $9.00
12/19/2022Jefferies Financial GroupUpgradeHold ➝ Buy$7.70 ➝ $11.00
11/21/2022HC WainwrightBoost TargetNeutral$8.00 ➝ $10.00
11/1/2022HC WainwrightDowngradeBuy ➝ Neutral$40.00 ➝ $8.00
10/24/2022Stifel NicolausLower TargetBuy$21.00 ➝ $18.00
10/21/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$19.00 ➝ $8.00
10/4/2022Wells Fargo & CompanyLower TargetOverweight$45.00 ➝ $9.00
9/14/2022CitigroupLower Target$27.00 ➝ $21.00
8/29/2022CitigroupLower TargetBuy$28.00 ➝ $27.00
5/27/2022Leerink PartnersBoost TargetOutperform$18.00 ➝ $19.00
5/23/2022HC WainwrightLower TargetBuy$44.00 ➝ $40.00
5/5/2022GuggenheimUpgradeNeutral ➝ Buy$14.00
3/15/2022Evercore ISIInitiated CoverageOutperform$15.00
2/28/2022CitigroupLower Target$53.00 ➝ $30.00
2/9/2022Wells Fargo & CompanyLower TargetOverweight$56.00 ➝ $48.00
2/1/2022Raymond JamesLower TargetOutperform$50.00 ➝ $27.00
1/20/2022Raymond JamesLower TargetOutperform$74.00 ➝ $62.00
1/6/2022Raymond JamesReiterated RatingOutperform$74.00
12/10/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform
12/9/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$74.00
11/15/2021Leerink PartnersReiterated RatingHold$43.00
11/10/2021Leerink PartnersLower TargetMarket Perform$28.00 ➝ $27.00
11/4/2021Raymond JamesSet TargetStrong-Buy$74.00
11/4/2021Leerink PartnersLower TargetMarket Perform$43.00 ➝ $28.00
10/6/2021Jefferies Financial GroupInitiated CoverageHold$32.00
9/30/2021Wells Fargo & CompanyReiterated RatingBuy$56.00
9/20/2021HC WainwrightReiterated RatingBuy$44.00
9/13/2021Raymond JamesSet TargetStrong-Buy$74.00
8/6/2021Raymond JamesReiterated RatingStrong-Buy$74.00
8/5/2021HC WainwrightLower TargetBuy$55.00 ➝ $44.00
5/7/2021HC WainwrightLower TargetBuy$57.00 ➝ $55.00
5/6/2021Raymond JamesSet TargetStrong-Buy$74.00
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$55.00
3/3/2021Raymond JamesSet TargetStrong-Buy$74.00
3/3/2021Leerink PartnersReiterated RatingOutperform ➝ Market Perform$50.00 ➝ $41.00
2/25/2021Raymond JamesSet TargetStrong-Buy$74.00
2/25/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$50.00 ➝ $41.00
2/8/2021HC WainwrightReiterated RatingBuy$57.00
2/3/2021Raymond JamesSet TargetStrong-Buy$74.00
1/29/2021CitigroupUpgradeNeutral ➝ Buy
1/28/2021Wells Fargo & CompanyLower Target$71.00 ➝ $56.00
1/28/2021Raymond JamesSet TargetStrong-Buy$74.00
1/28/2021Leerink PartnersLower TargetOutperform$66.00 ➝ $50.00
1/28/2021BarclaysLower TargetEqual Weight$47.00 ➝ $38.00
1/25/2021CitigroupDowngradeBuy ➝ Neutral$50.00 ➝ $53.00
1/19/2021Raymond JamesBoost TargetStrong-Buy$60.00 ➝ $74.00
1/12/2021Raymond JamesSet TargetStrong-Buy$60.00
1/12/2021Wells Fargo & CompanyBoost TargetOverweight$58.00 ➝ $71.00
1/12/2021Leerink PartnersBoost TargetOutperform$45.00 ➝ $66.00
12/2/2020Raymond JamesSet TargetStrong-Buy$60.00
11/17/2020Raymond JamesSet TargetStrong-Buy$60.00
11/4/2020Raymond JamesSet TargetStrong-Buy$60.00
10/26/2020Raymond JamesSet TargetStrong-Buy$60.00
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutral
8/6/2020Raymond JamesSet TargetStrong-Buy$60.00
8/6/2020Leerink PartnersInitiated CoverageOutperform$45.00
7/16/2020Raymond JamesSet TargetStrong-Buy$60.00
7/14/2020GuggenheimLower Target$54.00 ➝ $48.00
7/9/2020Raymond JamesSet TargetStrong-Buy$60.00
7/9/2020HC WainwrightLower TargetBuy$60.00 ➝ $54.00
6/14/2020Bloom BurtonReiterated RatingBuy
6/3/2020Raymond JamesSet TargetStrong-Buy$60.00
6/2/2020CitigroupBoost TargetBuy$49.00 ➝ $50.00
5/8/2020Paradigm CapitalReiterated RatingBuy$51.00
5/8/2020Raymond JamesSet TargetStrong-Buy$60.00
5/8/2020HC WainwrightReiterated RatingBuy$60.00
(Data available from 4/30/2020 forward)

News Sentiment Rating

1.30 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/2/2024
  • 6 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/1/2024
  • 6 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/1/2024
  • 15 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/31/2024
  • 18 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2025
  • 1 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2025
  • 27 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/31/2025
  • 23 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2025

Current Sentiment

  • 23 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zymeworks logo
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Read More

Today's Range

Now: $12.72
Low: $12.50
High: $12.79

50 Day Range

MA: $12.07
Low: $9.44
High: $14.39

52 Week Range

Now: $12.72
Low: $8.21
High: $17.70

Volume

37,257 shs

Average Volume

614,082 shs

Market Capitalization

$884.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

The following Wall Street research analysts have issued reports on Zymeworks in the last year: Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Lifesci Capital, Stifel Nicolaus, and Wells Fargo & Company.
View the latest analyst ratings for ZYME.

What is the current price target for Zymeworks?

0 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 65.1%. Lifesci Capital has the highest price target set, predicting ZYME will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $13.00 for Zymeworks in the next year.
View the latest price targets for ZYME.

What is the current consensus analyst rating for Zymeworks?

Zymeworks currently has 2 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ZYME.

What other companies compete with Zymeworks?

Other companies that are similar to Zymeworks include Scholar Rock, Akero Therapeutics, Viking Therapeutics, Xenon Pharmaceuticals and Catalyst Pharmaceuticals. Learn More about companies similar to Zymeworks.

How do I contact Zymeworks' investor relations team?

Zymeworks' physical mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company's listed phone number is (302) 274-8744 and its investor relations email address is [email protected]. The official website for Zymeworks is www.zymeworks.com. Learn More about contacing Zymeworks investor relations.